A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Clinical trial NCT07359820 · RECRUITING

Trial details

NCT number: NCT07359820
Sponsor: Elevar Therapeutics
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

FGFR2 Gene Fusion/Rearrangement Other Solid Tumors, Adult

Start date: 2026-06-04
Primary completion: 2027-09-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.